Home blood pressure variability has emerged as a critical predictor of cardiovascular events, stroke, and neurocognitive decline, with novel indices identifying high-risk patients.
How has HBPV research evolved from its foundational stages before 2020 to its current role in clinical practice, what are advancements, clinical relevance strengthened, technologies emerged, and challenges identified during the 2020-2026 period?
Home blood pressure variability is emerging as a critical predictor of cardiovascular risk, though interventional trials are needed to confirm if targeting it improves clinical outcomes.
Home blood pressure variability (HBPV) is transitioning from a niche research interest to a cornerstone in hypertension management. This review addresses the question: How has HBPV research evolved from its foundational stages before 2020 to its current role in clinical practice, what are advancements, clinical relevance strengthened, technologies emerged, and challenges identified during the 2020-2026 period? Non-standardized protocols have historically hindered the field, which now anchors on the evidence-based '722' protocol. Recent research highlights HBPV as a critical predictor of cardiovascular events, stroke, and neurocognitive decline, with novel indices such as the Time in Therapeutic Range and peak home blood pressure identifying high-risk patients. However, while the 2025 AHA/ACC guidelines elevate HBPM to a primary reference role, challenges remain regarding global equity in terms of device access. In conclusion, future efforts should focus on interventional trials to determine whether the specific reduction of HBPV independently improves clinical outcomes.
Posokhov et al. (Fri,) conducted a review in Hypertension. Home blood pressure variability (HBPV) was evaluated. Home blood pressure variability has emerged as a critical predictor of cardiovascular events, stroke, and neurocognitive decline, with novel indices identifying high-risk patients.